A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2023-04-23
Adverse events
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-05-24 (study day 23); relationship: N
Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2023-06-08 (study day 38); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-05 (study day 127); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-20 (study day 142); relationship: N
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-02 (study day 154); relationship: not assessed
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-10-27 (study day 179); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-16 (study day 199); relationship: Y
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-11-25 (study day 208); relationship: N
Data queries
No data queries.